



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/00, 38/02, 38/04, C07C 299/36, 299/30, 317/60, C07D 231/12, 333/22, 413/00	A1	(11) International Publication Number: WO 99/56761 (43) International Publication Date: 11 November 1999 (11.11.99)
(21) International Application Number: PCT/US99/09732 (22) International Filing Date: 4 May 1999 (04.05.99) (30) Priority Data: 09/072,428 4 May 1998 (04.05.98) US (71)(72) Applicant and Inventor: DAVAR, Gudarz [US/US]; Eight Myrtle Street, Jamaica Plain, MA 02130 (US). (74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHODS FOR TREATMENT OF PAIN (57) Abstract <p>The invention provides a method of determining whether a compound alleviates vasoconstriction-independent nerve pain mediated by endothelin-1 (ET-1). The method involves (i) determining whether the compound has the ability to inhibit a vasoconstriction-independent ET-1 action, and, if the compound has the inhibitory ability, then (ii) determining whether the compound reduces vasoconstriction-independent nerve pain by testing the compound in human patients suffering from pain mediated by the vasoconstriction-independent ET-1 action. The invention also includes a method of determining whether a compound alleviates pain caused by nerve injury in human patients. The method involves (i) determining whether the compound has the ability to inhibit an inflammatory leukocyte response, and, if the compound has the inhibitory ability, then (ii) testing the compound in human patients suffering from pain caused by nerve injury to determine whether the compound alleviates the pain.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHODS FOR TREATMENT OF PAIN

Background of the Invention

This invention relates to the treatment of pain and the identification of targets for pain treatment.

The sensation of pain can be caused by damage to sensory nerves (neuropathy), as well as damage to non-neural tissues. Pain that results from neuropathy is often referred to the deafferented regions of the body surface (Davar and Maciewicz, Neurol. Clin. 7: 289-304, 1989). In humans, painful peripheral neuropathy is often persistent, disabling and resistant to treatment with analgesic drugs including morphine (Sweet, Neurosurg. 15: 928-932, 1984).

Painful neuropathy often results from the direct effects of diseases, such as diabetes, varicella zoster virus (shingles) infection, trauma, autoimmune disorders, and connective tissue diseases. Alternatively, pain can result as a consequence of disease treatment, as is often observed in patients with AIDS and cancer who receive chemotherapy, radiation therapy or surgery.

One candidate mediator of pain associated with nerve injury is the inflammation response (Hafer-Macko et al., Ann. Neurol. 39: 625-635, 1995; Swartz et al., J. Neuropathol. 15:9-10, 1995; Schmidt et al., Muscle and Nerve 19: 474-487, 1996). The inflammation response in the nerve includes local edema, disruption of the perineurium, Wallerian degeneration, and infiltration of the endoneurium by progressively increasing numbers of leukocytes (Sommer et al., J. Neuropathol. Exp. Neurol. 52: 223-233, 1993; Sommer et al., J. Neuropathol. Exp. Neurol 54: 635-643, 1995). Such signs of inflammation are well developed following trauma to the rat sciatic nerve (Avellino et al., Exp. Neurol. 136: 183-

-2-

194, 1995; Dahlin, *Neurosci. Lett.* 184: 5-8, 1992; Danielsen et al., *Biomaterials* 14: 1180-1185, 1993; Monaco et al., *J. Neurocytol.* 21: 623-634, 1992; Perry et al., *J. Exp. Med.* 165: 1218-1223, 1987).

Another potential mediator of nerve pain is the potent vasoconstrictor peptide, endothelin-1 (ET-1) (Hickey et al., *Am. J. Physiol.* 248: C550-C556, 1985; Yanagisawa et al., *Nature* 332: 411-415, 1988). Administration of epinephrine (≥ 10 nM) is known to reduce sciatic endoneurial blood flow to a degree similar to that observed with similar concentrations of ET-1 (Zochodne et al., *Am. J. Physiol.* 263 (Heart Circ. Physiol. 32): H1806-H1810, 1992). The intraperitoneal administration of ET-1 produces an abdominal writhing response in rodents that is ET-1 receptor-mediated. This response may be behavioral evidence of acute pain (Raffa et al., *Exp. Ther.* 276: 647-651, 1996a; Raffa et al., *J. Pharmacol. Exp. Ther.* 278: 1-7, 1996b). In humans, the intra-arterial administration of ET-1 is reported to induce severe pain that is associated with prolonged touch-evoked allodynia in the injected limb (Dahlof et al., *J. Hypertension* 8: 811-818, 1990). The ET_A subtype receptor-dependent effects are G-protein coupled and may be linked to L-type calcium channel signaling as observed in other tissues (Reynolds et al., *Biochem. Biophys. Res. Commun.* 160: 868-873, 1989). ET-1 is secreted in high concentrations by metastatic prostate cancer cells (Nelson et al., *Nature Medicine* 1(9): 944-949, 1995).

Cancer pain affects over 75% of patients with metastatic cancer. Thus, over 1 million patients in the United States and well over 9 million patients worldwide suffer cancer pain (Bonica, *The Management of Pain*, second edition, ed: J.J. Bonica, pages 400-460, 1990). The pain is often debilitating and difficult to treat, especially in patients with advanced

disease. In patients with metastatic cancer of the prostate, pain treatment often requires very large doses of either systemic or intraspinal opioids, often an insufficient pain treatment that produces undesirable side-effects (Cherny and Portenoy, Textbook of Pain, third edition, eds: P.D. Wall and R. Melzack, pages 787-823, 1994). Clearly, a better understanding of the mechanisms that mediate the sensation of pain associated with neuropathy and cancer pain will lead to new target identification and the development of more beneficial pain treatments.

Summary of the Invention

The invention provides a method of determining whether a compound alleviates vasoconstriction-independent nerve pain mediated by endothelin-1 (ET-1). The method involves (i) determining whether the compound has the ability to inhibit a vasoconstriction-independent ET-1 action, and, if the compound has the inhibitory ability, then ii) determining whether the compound reduces vasoconstriction-independent nerve pain by testing the compound in human patients suffering from pain mediated by the vasoconstriction-independent ET-1 action.

The method of determining whether the compound has the ability to inhibit a vasoconstriction-independent ET-1 action can involve an *in vitro* assay composed of steps such as the following: (i) layering functional ET or ET_A receptors, e.g. in samples of neuronal or vascular cells or neuronal or vascular cell membrane preparations, onto culture plates, e.g., scintillator-coated 96-well plates, in paired samples that contain or lack the compound; (ii) adding ET receptor ligand, e.g. [¹²⁵I]ET-1, measure specific binding, and assess ability of compound to inhibit ligand binding; if inhibitory compounds are identified, then (iii) further characterizing the agonist or antagonist effect of the compound on the activation of

-4-

intracellular signaling, e.g. on G-protein coupled signaling, in cell-based assays; if ligands with antagonist or partial antagonist activity are identified, then (iv) screening compounds in an *in vivo* model, e.g., the direct sciatic nerve ET-1 application model, and assessing the effects on ET-1 induced pain behavior, e.g., hindpaw flinching.

5 Preferably, the compound inhibits the ET-1 action at a nerve ET receptor. Most preferably, the compound inhibits the ET-1 action at a nerve ET_A receptor.

The invention also includes a method of treating a human patient to alleviate pain caused by vasoconstriction-independent ET-1 action. The method involves administering an effective amount of an ET inhibitor, e.g. an inhibitor from the group of sulfoxazole, TBC-
10 11251, BQ-123, PD 156707, A-127722, LU 135252, BQ-788, Bosentan, TAK-044, SB 209670, and SB 217242, as described in Ann. Reports in Medicinal Chemistry, Section II, Ch. 7, Endothelin Inhibitors, pages 61-70, 1997 (ed. A.M. Doherty, Academic Press, Inc.).

Preferably, the ET inhibitor is an ET_A-selective inhibitor from the group of TBC-
11251, BQ-123, PD 156707, A-127722, and LU 135252, and the compound inhibits ET-1
15 action at a ET_A receptor on the nerve.

The method of treatment of the invention can be used to alleviate pain in a patient with a condition associated with increased ET-1 levels and for the treatment of diseases such as metastatic prostate cancer, metastatic breast cancer, sickle cell anemia, and other painful
vascular diseases, e.g., migraine headaches, Reynaud's disease, and peripheral vascular
20 disease.

The invention also includes a method of determining whether a compound alleviates pain caused by nerve injury in human patients. The method involves (i) determining whether the compound has the ability to inhibit an inflammatory leukocyte response, and, if the

compound has the inhibitory ability, then (ii) testing the compound in human patients suffering from pain caused by nerve injury to determine whether the compound alleviates the pain.

The method of determining whether the compound has the ability to inhibit an inflammatory leukocyte response can be carried out by conducting an *in vitro* assay, such as (i) harvesting leukocytes, e.g. rat leukocytes, and (ii) placing leukocytes in wells of a culture plate, e.g., a radially-distributed agarose culture plate, in paired samples which either contain or lack the compound, adjacent to wells containing minced nerve samples, e.g. minced rat sciatic nerve, (iii) incubating the plates for sufficient time, e.g. 8-12 hours, to allow leukocyte migration toward the nerve sample well, (iv) fixing and staining the leukocytes, and (v) quantifying the degree of leukocyte migration to assess the ability of the compound to inhibit leukocyte migration.

The invention also provides a method of treating a human patient to alleviate pain caused by nerve injury. The method involves administering an effective amount of a leukocyte migration inhibitor, e.g., itraconazole, mepaerine, ketoconazole, chloroquine, hydroxychloroquine, dipyridamole, or feldene.

One advantage of the present invention is the identification of specific, novel targets to use for developing new pain treatments. Given these targets, candidate compounds never before considered as effective pain treatments can be analyzed. For example, using these new targets, screening assays can be performed to identify new candidate compounds previously missed in other anti-pain screens. In addition, compounds that have previously been identified as affecting the targets of the invention, i.e., compounds identified as ET inhibitors and leukocyte migration inhibitors, can be reanalyzed for their ability to alleviate pain.

Other features and advantages of the invention will be apparent from the following detailed description thereof, and from the claims.

Brief Description of the Drawings

Fig. 1 is a graph showing the effect of 400 μ M ET-1 applied at $t = -5$ min on the frequency of hindpaw flinching over a period of 60 min. Significant differences ($*p \leq 0.05$; $**p \leq 0.0001$) in the magnitude of hindpaw flinching were observed at nearly every time point when ET-1 ($n = 10$) and PBS ($n = 10$) treated animals were compared.

Fig. 2 is a graph showing the effect of systemic morphine ($n = 5$) administered prior to ET-1 ($n = 10$), and morphine+naloxone ($n = 5$) on ET-1-induced hindpaw flinching. Differences between ET-1 and morphine-treated rats are present at all time points. Significant differences observed between ET-1 and morphine+naloxone-treated rats ($*p \leq 0.05$; $**p \leq 0.0001$). There is no difference between these groups 15 min after administration naloxone (arrow), consistent with a reversal of the effect of morphine at this time point. ET-1-treated animals are those described above in Fig.1.

Fig. 3 is a graph showing the effect of BQ-123 ($n = 10$) (3 mM) and BQ-788 ($n = 4$) (3 mM) administered 20, 10, and 0 min prior to ET-1 (400 μ M) on ET-1-induced hindpaw flinching. Differences between BQ-123 and ET-1 are significant at every time point after 5 min. Differences between BQ-788 and ET-1-treated animals are significant at 45 and 50 min. Animals treated with ET-1 alone are those described above in Fig.1.

-7-

Fig. 4A is a graph showing the effect of applying 1.6, 8, 12, 16, and 32 nanomoles of ET-1 (equivalent to 40, 200, 300, 400, and 800 μ M, respectively) onto rat sciatic nerve. The group treated with 16 nanomoles are those described above in Fig. 1. Fig. 4B shows the ET-1 dose response of hindpaw flinching at 10 minutes post ET-1 administration. The half-maximal effect is estimated to occur at a concentration of 300 μ M.

Fig. 5 is a graph showing the comparison of peak frequency of hindpaw flinching and the area-under-the-curve analysis for each concentration of ET-1.

Fig. 6 is a graph showing the effect of repeat administration of 400 μ M ET-1 on hindpaw flinching. Significant differences (* $p \leq 0.05$; ** $p \leq 0.0001$) in the frequency of hindpaw flinching were observed at most time points when the initial and repeat dose groups were compared.

Fig. 7 is a graph showing the response of fura-2-loaded embryonic sensory neurons to the superfusion of 400 μ l of 13.5 μ M ET-1 in PBS (pH = 7.4) into an 0.5 ml perfusion chamber. The arrow points to the time of application of ET-1.

Figs. 8A and 8B are graphs showing a comparison of mean latencies to hindpaw withdrawal from a thermal painful stimulus in CCI rats receiving saline (Fig. 8A), or 1.5mg/kg/day dexamethasone (DEX) (ip) (Fig 8B). In Fig. 8A, hindpaw withdrawal latencies ipsilateral to CCI are reduced from 3-10 days in saline-treated rats ($p < .005$, Wilcoxon Signed Rank test). In Fig. 8B, hindpaw withdrawal latencies to CCI are unchanged from baseline

and not different between hindpaws until 10 days after CCI in DEX-treated rats, when compared with saline-treated rats ($p < .05$, ANOVA).

Fig. 9 is a graph showing a comparison of the mean number of leukocytic profiles per high power field (HPF) in representative 5 μm sections of sciatic nerve from saline- and DEX-treated CCI rats, and the mean difference (unoperated-operated) in hindpaw withdrawal latencies from 3-10 days. Small increases in leukocyte number above baseline are associated with minimal differences in hindpaw withdrawal latency. As numbers increase, the difference scores increase quickly and reach a plateau beyond which further increases in leukocyte number do not affect withdrawal latency..

Figs. 10A and 10B are graphs showing the effect of cyclophosphamide treatment (100 mg/kg., ip, on alternate days x 3 days, prior to CCI) on mean latencies to hindpaw withdrawal from a thermal painful stimulus prior to and following sciatic nerve CCI. In Fig. 10A, hindpaw withdrawal latencies ipsilateral to CCI appear reduced from 3-10 days in saline-treated rats. In Fig. 10B, hindpaw withdrawal latencies to CCI are not different between hindpaws until 10 days after CCI in CYCLO-treated rats, when circulating leukocyte counts have recovered to near normal values.

Figs. 11A and 11B are graphs showing the comparable effects of saline (Fig. 11A) and cyclophosphamide (Fig. 11B) treatment on hindpaw withdrawal latencies to thermal stimulation in normal rats. Although no apparent differences between hindpaws were observed in either treatment group, a trend toward bilateral hyperresponsiveness was seen in

both groups and was likely due to handling (multiple injections). For these experiments only, different groups of treated animals were tested (alternating fashion) on each test day to limit the amount of blood drawn.

Detailed Description of the Invention

ET-1 mediated pain

We applied ET-1 and other drugs directly to the sciatic nerve in rats. Hindpaw flinching, a marker of pain behavior (Dubuisson and Dennis, Pain 4: 161-174, 1977), was used to quantify the pain response. The results of these experiments (described in detail below) led to the discovery that ET-1 acts directly at the nerve and elicits pain, at least in part, through a vasoconstriction-independent mechanism.

Methods

Surgical Procedures. Adult male Sprague Dawley rats (175-225g) were anesthetized with an intermediate-onset, short-acting volatile anesthetic (Sevofluorane, Abbott Laboratories, North Chicago, IL). After shaving of the hair over the left or right flank and incision of the skin, blunt dissection was made through the biceps femoris, the sciatic nerve exposed by careful microdissection away from the surrounding connective tissue, and gently elevated by insertion of a small curved hemostat placed beneath it. Following drug administration, as described below, the biceps femoris was closed with a single silk suture, and the skin closed with surgical staples.

Drug administration. The following drugs were applied epineurially: 1) 40-800 μ M endothelin-1 (ET-1) (synthetic, 98% pure peptide content, American Peptides Co.,

-10-

Sunnyvale, CA); 2) the selective endothelin-A receptor antagonist, BQ-123 (American Peptides Co.; Sunnyvale, CA) at 3 mM; 3) the selective endothelin-B receptor antagonist, BQ-788 (American Peptides Co.; Sunnyvale, CA) at 3 mM; and 400 μ M epinephrine (American Regent Laboratories, Inc., Shirley, NY).

5 All drugs were dissolved in phosphate buffered saline (PBS, pH = 7.4), and applied in 40 μ l volumes to the epineurial surface of the exposed sciatic nerve (n = 10 rats/condition). The total time for each drug application was 3-4 min. BQ-123 and BQ-788 were applied in 3 stages: 20 min prior to, 10 min prior to and 30 sec before ET-1 application. PBS was administered to control animals. Excess drug or PBS solution was absorbed by cotton gauze
10 placed at the edge of the exposed nerve.

Morphine was administered systemically immediately before anesthesia (10 mg/kg, ip). Naloxone was administered systemically 20 min after the completion of ET-1 application (2 mg/kg, ip).

In experiments involving repeated administration of ET-1, animals were
15 re-anesthetized 75-80 min after surgery (time point after which no further hindpaw flinching was observed, as described below), and 400 μ M ET-1 was applied in the same volume, as described above. Behavioral evaluation was performed, as described below, for an additional 60 min.

Behavioral evaluation. After 5 min, the rats demonstrated complete recovery from
20 the effects of general anesthesia. Behavioral measurements were then performed with animals freely moving on a flat surface enclosed by an inverted large Plexiglas cage. The total number of ipsilateral and contralateral spontaneous hindpaw flinches (operationally defined as complete lifting of the hindpaw off the testing surface) were counted for

-11-

consecutive 5 minute periods for a total 60 minute observation period. The total duration of hindpaw lifting and time spent exploring were also recorded.

Microfluorometry in E1A cells. E1A cells (retrovirally-transformed rat dorsal root ganglion cells) were grown as a monolayer on poly-L-lysine coated coverslips in Dulbecco's modified eagle media supplemented with 10% fetal bovine serum at 37°C in a humified atmosphere (5% CO₂-95% air). Cells were used 48-72 hours after plating, at a confluence of 75 to 90%. The concentration of intracellular calcium was determined by dual excitation microfluorometry, using the calcium sensitive dye Fura-2 (Grynkiewicz, et.al., J. Biol. Chem. 260: 3440-3450, 1985). E1A cells were washed once with D-PBS (with Ca⁺⁺) and then incubated for 30 min at room temperature in D-PBS (with Ca⁺⁺) containing 7.5 μM Fura-2/AM and 0.00125% (wt/vol) pluronic-DMSO. The cells were then washed twice in D-PBS (with Ca⁺⁺) and incubated for an additional 30 minutes to allow cleavage of the Fura-2/AM to the active Fura-2.

Experiments were conducted with the coverslips in a perfusion chamber of 0.4 ml, with a constant flow rate of 4 ml/min. Each coverslip was equilibrated in D-PBS for 2 min prior to beginning an experiment. ET-1 was delivered into a catheter attached to the perfusion chamber such that the lag time from addition of ET-1 until it reached the perfusion chamber was about 30 sec. ET-1 was given as a pulse in a 400 μl volume.

Microfluorometry was performed with an inverted epifluorescence microscope connected to a light source which provided two alternating wavelengths (Photon Technology International Deltascan). The excited wavelengths were 340 and 380 nm. Emitted light was passed through a 510 nm interference filter to a photomultiplier tube. Background fluorescence was subtracted from each trial.

Data Analysis. The peak frequency of hindpaw flinching, effects at 10 min post-drug administration, and area-under-the-curve (without approximation) from 0-60 min were all used to describe response-concentration functions.

Statistical analysis of differences between groups was performed by two-tailed Student's t-test, ANOVA, factorial ANOVA, and Fisher's Protected Least Significant Difference test (STAT View, SAS Statistical Institute, Cary, NC).

Results

ET-1 effects. Repetitive, spontaneous hindpaw flinching was increased in ET-1-treated rats from 10-60 min post-administration (Fig. 1). ET-1 administration also caused postural changes, i.e., flexion of the plantar toes and mild eversion of the foot. These postural changes are evidence of a partial sciatic motor neuropathy. The increased flinching behavior and the postural changes demonstrated similar time courses, both peaked by 30 min and resolved to near baseline by 60 min. At times, flinching behavior was associated with sustained elevation of the hindpaw lasting up to 2 minutes.

The hindpaw flinching was associated with a partial and reversible sciatic motor neuropathy, suggesting a direct ET-1 action on the nerve. A direct ET-1 action is supported by evidence that administration of the same concentration of ET-1 onto or into the muscles surrounding, but not innervated by, the sciatic nerve caused neither increased hindpaw flinching nor postural changes. Thus, the observed behavioral effect was not due to muscle irritation and ensuing motor hyperreflexia. However, animals did show signs of generalized distress (chromodacryorrhea, or red tears) following ET-1 application to the muscle.

Effects of morphine and naloxone on ET-1 induced hindpaw flinching. Morphine

(10 mg/kg, ip) was administered immediately before anesthesia and the frequency of hindpaw flinches counted. At this dose, morphine completely blocked flinching induced by ET-1 (Fig. 2). Naloxone (2 mg/kg, ip), administered 20 min after ET-1, rapidly reversed the effect of morphine for approximately 10 min (Fig. 2), consistent with naloxone's known short duration of action. Given the effects of morphine and naloxone, the following mechanisms are clear:

1) ET-1 induces pain behavior that is blocked by opioids, and 2) morphine blockade is mediated through an opioid receptor-dependent mechanism. Therefore, the pain behavior elicited by ET-1 was consistent with the pain associated with metastatic prostate cancer, which is also blocked by opioids. Animals in these experiments showed minimal signs of sedation, but only at the beginning of testing, as determined by their level of alertness and time spent in exploratory behavior.

Effects of epinephrine on hindpaw flinching. We applied epinephrine (400 μ M) to sciatic nerve. This dose produces a maximal vasoconstriction effect, yet no evidence of hindpaw flinching was observed throughout the 60 min observation period. Therefore, the ET-1 induced increase in hindpaw flinching occurs independent of ET-1's vasoconstriction effect. Alternative sites of ET-1 action besides the microvessels include Schwann cells or sensory afferent neurons themselves.

ET-1 effects are ET_A receptor-dependent. ET receptor subtypes, ET_A and ET_B are selectively antagonized by BQ-123 and BQ-788, respectively. BQ-123 completely blocked the ET-1 induced hindpaw flinching from 10-60 min post-ET-1 administration, whereas BQ-788 reduced hindpaw flinching significantly only at the 40 and 45 min timepoints (Figure 3). The concentrations chosen for these antagonists (3 mM) were well in excess of their KI's in other tissues (Marsault et al., Am. J. Physiol. 264 (Cell Physiol. 33): C687-C693, 1993;

Ishikawa et al., J. Med. Chem. 35(11): 2139-2142, 1992). These results indicate that the ET_A subtype of receptor on neurons mediates the ET-1 induced pain behavior.

Dose-dependent effects of ET-1. ET-1 was administered to sciatic nerve as previously described in concentrations ranging from 40-800 μ M. The frequency of hindpaw
5 flinching increased in a monotonic (at early time points), dose-dependent, non-linear fashion. The maximum frequency was achieved with 400 μ M ET-1 (Fig. 4A and B). The initial rate-of-rise in hindpaw flinching correlated with increasing ET-1 concentration. However, the time elapsed for peak response after ET-1 administration was longer for the higher concentrations (Fig. 4A).

10 Similar ET-1 behaviors were observed whether peak frequency effects or the area under the curve (AUC) were analyzed (Fig. 5). There was no evidence of receptor-limited effects (i.e. saturation), and overall determinations of concentrations producing a half-maximal effect were limited by the apparent inhibitory effect observed at high concentration (800 μ M).

15 **Effects of repeated administration.** Following administration of ET-1 (400 μ M) and a 60 min testing period, a second treatment of 400 μ M ET-1 was administered 15-20 min after completion of the first testing period. The second ET-1 treatment did not produce hindpaw flinching that was significantly different from controls (as shown in Fig. 1) over the second, post-administration 60 min observation period (Fig. 6).

20 **ET-1 has a direct effect on neuron-derived cells in culture.** Microfluorometry analysis in E1A cells during ET-1 administration revealed a large, rapid, and transient increase in Fura-2 fluorescence (Fig. 7). This increase demonstrates that ET-1 induced a rise in intracellular Ca⁺⁺ in the E1A cells from the normal resting level (50-100 nM) to near 500

-15-

nM. This change is as large as that produced by KCl (30 mM)-induced depolarization. These effects are further evidence that ET-1 produces a direct effect on neural tissue. Following ET-1, a slowly decaying plateau phase was present over the subsequent 5 min. This plateau is likely related to the diffusion of ET-1 across the perineurium.

5 **Summary and Conclusions**

The studies described above provide several important observations: 1) ET-1 applied to rat sciatic nerve *in vivo* induces ipsilateral hindpaw flinching behavior, a behavioral pain response; 2) systemic treatment with morphine prior to ET-1 administration blocks this flinching behavior, a blockade which is reversed by systemic naloxone, 3) concentrations of epinephrine known to induce the same degree of vasoconstriction in sciatic nerve as does ET-1 do not produce increased hindpaw flinching behavior that is different from vehicle, 4) the effects of ET-1 on hindpaw flinching are non-monotonically dose-dependent, and 5) ET-1 has a direct effect on neurons, increasing intracellular Ca^{++} in cultured embryonic sensory neurons.

15 Given these results, we conclude that ET-1 applied to rat sciatic nerve 1) produces a direct effect on sensory neurons, and 2) induces pain behavior via a mechanism independent of vasoconstriction of sciatic nerve microvessels. Therefore, the inhibition of ET-1's vasoconstriction-independent mechanism of causing pain is an effective pain treatment, especially under conditions where ET-1 levels are elevated in a patient, such as metastatic prostate cancer. Furthermore, given that ET-1 acts directly on the sensory neuron ET_A receptor, the ET_A receptor is an important therapeutic target.

20

Leukocyte infiltration-mediated pain

We studied the role of leukocyte migration in eliciting nerve pain. Nerve injury was induced using the chronic constrictive injury procedure (CCI) on rat sciatic nerve. The results of these studies (described in detail below) led to the discovery that the pain response induced by nerve injury is correlated with leukocyte migration to the injury site. Furthermore, the pain response can be inhibited if leukocyte migration to the injury site is reduced.

Methods

CCI surgery. The sciatic nerve of a rat was exposed after blunt dissection of the biceps femoris. Four chromic gut ligatures (4-0) were placed around a 7 mm section of sciatic nerve in the mid-thigh region. The ligatures were applied so that they constricted the diameter of the nerve just enough to impede circulation through the superficial vasculature (as visualized under an operating microscope at 40X). Sham-operated rats received an identical exposure of the left sciatic nerve without CCI. A coding system blinded the investigators to the nature of the surgery performed on individual rats.

Histology. To compare the extent and type of cellular inflammation around the peripheral nerve due to CCI between DEX- and saline-treated rats, the ligated sciatic nerve was processed for histological analysis. At 3, 5, 7, and 10 days post-CCI, animals were euthanized with 100 mg/kg intraperitoneal sodium pentobarbital, and then transcardially perfused first with 50 ml of cold 0.9% NaCl, 1 ml/g body weight of 4% paraformaldehyde in 0.01 M phosphate buffered saline, pH 7.4 (PBS). A 2-3 cm section of sciatic nerve, or a 1 cm section of L5 and L6 spinal nerves, which included material at the ligation site, as well as that

-17-

just proximal and distal to ligation, was placed in 0.01 M PBS, 4% paraformaldehyde to post-fix for 2 hours. Tissue was then embedded in paraffin, cut in 10-30 μ m sections on a vibratome, and placed on glass slides. Slides were deparaffinized and then hydrated in distilled water prior to staining in freshly filtered Harris' hematoxylin for 6-15 min. After washing in running tap water for 2-5 min, sections were differentiated in 1% acid alcohol, washed briefly in tap water, and then placed in weak ammonia water until sections are bright blue. The sections were then washed thoroughly in running tap water, transferred to 80% ethanol, and then counterstained in eosin-phloxine solution prior to dehydration and mounting with Permount.

Quantitation of leukocytes in nerve sections. To detect leukocytes in injured peripheral nerve, both cellular and nuclear stains (H and E, respectively) were used. To be included in the leukocyte cell count, leukocytes had to 1) have a nucleus which was clearly visible and characteristic of an infiltrating macrophage (bean-shaped nucleus), neutrophil (polymorphic nucleus) or lymphocyte (dense nucleus that fills the cytoplasm); 2) have a "foamy" macrophage appearance typical of a myelin-ingesting phagocytes; and 3) be present within the endoneurial space. Cells present within vascular spaces or containing nuclei that could not be clearly differentiated from activated Schwann cells, fibroblasts or endothelial cells were not counted.

Blood cell counts and replacement. To obtain syngeneic leukocytes for replacement in animals depleted of leukocytes as a result of CYCLO treatment, we centrifuged whole blood from normal rats (1500 rpm, 10 min, in a clinical centrifuge). The buffy coat (which contains primarily leukocytes) was removed under sterile conditions and injected into experimental animals.

Leukocyte counts were made at subsequent time points to determine the need for additional leukocyte supplementation. For CYCLO-treated animals, all the leukocytes in the buffy coat from one normal animal are needed to fully replenish those lost because of treatment. For CSF-treated animals, smaller numbers of leukocytes (a portion of buffy coat volume to be determined) are likely to be needed to augment the effect of CCI.

Complete blood counts were serially determined on all animals receiving treatments. Total white blood cell counts in normal rats are approximately $9 \times 10^3 \mu\text{l}$ in normal animals, increase slightly in CCI rats, and are markedly reduced to $<1 \times 10^3 / \mu\text{l}$ in CYCLO-treated CCI rats.

Statistical analyses. Differences within groups were analyzed using the Wilcoxon signed rank test. Differences between groups were analyzed by two-way ANOVA and Fisher's protected least significant difference test for post-hoc comparisons.

Results

Dexamethasone inhibits CCI-induced pain sensitivity. Following a chronic constrictive injury (CCI) procedure on rat sciatic nerves, the rats demonstrated increased pain sensitivity (thermal hyperalgesia) in the ipsilateral hindpaw when compared to both baseline values and the contralateral hindpaw values (Fig 8A). Thermal hyperalgesia was defined as a reduction in the latency to hindpaw withdrawal during a thermal stimulus applied to the plantar surface. Dexamethasone (DEX) (1.5 mg/kg, i.p.), administered to rats 24 hr prior to, and daily for 10 days after CCI, delayed the onset of thermal hyperalgesia when compared to CCI treatment alone (Fig. 8B), eliminating differences from both baseline values and contralateral hindpaw values for a duration of 3-7 days post-CCI. Presumably, chemotactic

signals overwhelmed the effects of DEX by 10 days to account for differences from baseline and between hindpaws at this timepoint (Fig. 8B).

Dexamethasone inhibits CCI-induced leukocyte migration. Most significantly, DEX also delayed the onset of the leukocytic inflammatory response to CCI (Table I).

5 Comparison of leukocyte infiltration and hindpaw withdrawal latencies (Fig. 9) revealed that hyperalgesia (seen at 3 days in saline-treated CCI rats and at 7 days in DEX-treated rats) emerged when about 25-30 leukocytes/40x high power field (HPF) (or approximately 10^5 cells/7 mm segment of intact nerve) were present in the region of the nerve injury. Given that there was no hyperalgesia in DEX-treated animals when there were <13 leukocytes/40x HPF
10 (approximately 5×10^4 /7 mm segment of intact nerve), it is likely that a threshold number of leukocytes is required for the development or maintenance of sustained hyperalgesia.

Cyclophosphamide treatment inhibits CCI-induced leukocyte infiltration and hyperalgesia. As another means of reducing the leukocyte inflammation response, the alkylating agent cyclophosphamide (CYCLO) (Sigma, St. Louis, MO) was pre-operatively
15 administered (100 mg/kg on alternate days x 3 days), and markedly reduced circulating leukocyte numbers. In CCI-treated rats, CYCLO also blocked the hyperalgesia response, until leukocyte counts returned toward normal 10 days post-surgery (Fig. 10A, 10B, and Table II).

This effect was not caused by CYCLO-associated toxicity, because CYCLO had no analgesic
20 effects with respect to thermal pain stimulation in normal animals (Fig. 11A and B).

Anti-CD18 antibody treatment inhibits CCI-induced hyperalgesia. Systemic administration of an anti-CD18 antibody (WT.3) 1 day pre-CCI to 6 days post-CCI completely blocked pain behavior in the rats for this period of time.

Summary and Conclusions

As the following results demonstrate, the leukocytic inflammatory response plays a significant role in mediating the pain behavior that follows CCI in the rat. This conclusion results from the following experimental results: 1) suppression of leukocyte chemotaxis and activity, via dexamethasone treatment, blocks hindpaw thermal hyperalgesia in CCI rats until intraneural leukocytes reach a 'threshold' value; and 2) depletion of leukocytes in CCI rats with cyclophosphamide or anti-CD18 antibody also block hyperalgesia in CCI rats until circulating leukocyte counts recover.

Other Embodiments

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the appended claims.

What is claimed is:

Claims

1. A method of determining whether a compound alleviates vasoconstriction-independent nerve pain mediated by endothelin-1 (ET-1), said method comprising the steps of:

5 a) determining whether said compound has the ability to inhibit a vasoconstriction-independent ET-1 action, and then, if said compound has said inhibitory ability,

b) testing said compound in a human patient suffering from pain mediated by said vasoconstriction-independent ET-1 action to determine whether the compound alleviates said pain.

10 2. The method of claim 1, wherein step (a) comprises conducting an *in vitro* assay to determine whether said compound is an antagonist and partial antagonist of ET-1 receptor binding or receptor activation.

3. The method of claim 1, wherein the site of said vasoconstriction-independent ET-1 action is at a nerve ET receptor.

15 4. The method of claim 3, wherein said nerve ET receptor is an ET_A receptor.

5. Use of a compound selected from the group consisting of sulfoxazole, TBC-11251, BQ-123, PD 156707, A-127722, LU 135252, BQ-788, Bosentan, TAK-044, SB 209670, and SB 217242 for the preparation of a pharmaceutical composition for alleviating

-22-

pain caused by vasoconstriction-independent ET-1 action in a human patient.

6. The use of claim 5, wherein said compound is TBC-11251, BQ-123, PD 156707, A-127722, or LU 135252.

5 7. The use of claim 5, wherein the site of said vasoconstriction-independent ET-1 action is at a nerve ET receptor.

8. The use of claim 6, wherein the site of said vasoconstriction-independent ET-1 action is at a nerve ET_A receptor.

9. The use of claim 5, wherein said patient has a condition associated with increased ET-1.

10 10. The use of claim 5, wherein said patient has metastatic prostate cancer.

11. The use of claim 5, wherein said patient has metastatic breast cancer.

12. The use of claim 5, wherein said patient has sickle cell anemia.

13. A method of determining whether a compound alleviates pain caused by nerve injury in human patients, said method comprising the steps of:

15 a) determining whether said compound has the ability to inhibit an

-23-

inflammatory leukocyte response, and then, if said compound has said inhibitory ability,

b) testing said compound in human patients suffering from pain caused by nerve injury to determine whether said compound alleviates said pain.

14. The method of claim 13, wherein step (a) comprises conducting an *in vitro* assay.

5 15. Use of a compound selected from the group consisting of itraconazole, mepaerine, ketoconazole, chloroquine, hydroxychloroquine, dipyridamole, and feldene for the preparation of a pharmaceutical composition for alleviating pain caused by nerve injury in a human patient.




FIGURE 1




FIGURE 2




FIGURE 3

4/11




FIGURE 4A




FIGURE 4B

5/11




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8A




FIGURE 8B




FIGURE 9




FIGURE 10A




FIGURE 10B




FIGURE 11A




FIGURE 11B

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/09732

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,658,943 A (BERRYMAN et al) 19 August 1997, columns 7-8.	1-4 13-14
Y	US 5,648,486 A (CAI et al) 15 July 1997, col. 26, lines 15-26 and col. 28, lines 41-49.	13-14
A	US 5,504,215 A (TALLEY et al) 02 April 1996, abstract and col. 1.	13-15
Y	CHENG et al. Endothelin Inhibitors. Annual Reports in Medicinal Chemistry, 1997, Vol. 32, pages 61-70, see entire document.	5-12 and 15

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 JULY 1999

Date of mailing of the international search report

30 AUG 1999

Name and mailing address of the ISA: US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FATEMEH T. MOEZIE

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/09732

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NELSON et al. Identification of Endothelin-1 in the Pathophysiology of Metastatic Adenocarcinoma of the Prostate. Nature Medicine. September 1995, Vol. 1, No. 9, pages 944-949, espacially pages 944-945.	5-12 and 15
A	FERRERIRA et al. Endothelin-1 Participation in Overt and Inflammatory Pain. Journal of Cardiovascular Pharmacology. 1989, Vol. 13, Suppl. 5, S220-S222.	1-15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/09732

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 38/00, 38/02, 38/04; C07C 299/36, 299/30, 317/60; C07D 231/12, 333.22, 413/00

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

514/466, 536, 567, 63, 617; 544/124, 283, 284; 549/435, 444, 494, 73, 74, 75, 77, 78, 79, 80, 473, 475, 476, 477, 478, 480, 483, 484, 487, 488, 497, 498, 499, 500, 501, 502; 560/40; 562/439, 436; 556/419

B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

514/466, 536, 567, 63, 617; 544/124, 283, 284; 549/435, 444, 494, 73, 74, 75, 77, 78, 79, 80, 473, 475, 476, 477, 478, 480, 483, 484, 487, 488, 497, 498, 499, 500, 501, 502; 560/40; 562/439, 436; 556/419

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

STN: MEDLINE, CAPLUS, BIOSIS, EMBASE

Author search

search terms: sulfisoxazole, pain, inflammatory and response, et and antagonist, BQ-123, Bosentan, TAK-044, itraconazole, mepaerine, ketoconazole, chloroquine, dipyridamole, feldene, human, patient, in-vitro